Last reviewed · How we verify
Amlodipine besylate combined Spironolactone
At a glance
| Generic name | Amlodipine besylate combined Spironolactone |
|---|---|
| Sponsor | Third Military Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Arterial Stiffness and Blood Pressure (NA)
- Statin Combined with Amlodipine Treats Primary Aldosteronism (PHASE4)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension (PHASE3)
- The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure (PHASE4)
- Recurrent Stroke Prevention Clinical Outcome Study (PHASE4)
- STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia) (PHASE4)
- Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: